Zaandam, the Netherlands, September 12, 2017 - Ahold Delhaize has repurchased 1,016,701 of Ahold Delhaize common shares in the period from September 4, 2017 up to and including September 8, 2017. The shares were repurchased at an average price of €15.16 per share for a total consideration of €15.4 million. These repurchases were made as part of the €1 billion share buyback program announced on December 7, 2016.
The total number of shares repurchased under this program to date is 42,189,284 common shares for a total consideration of €784 million.
Download the share buyback transactions excel sheet for detailed individual transaction information from www.aholddelhaize.com/en/investors/share-information/share-buy-back-programs/


Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



